CD4 and cancer: Cancer cells can often escape from immune surveillance in the TME to inhibit the cytotoxic function of tumor-antagonizing immune cells including CD8+ cytotoxic T cells and effector CD4+ T cells via EGFR/PD-L1 signaling 50, 51.